darlifarnib
darlifarnib: sourced relationships with 1 company · 1 clinical trial tracked.
darlifarnib evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could darlifarnib → KURA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Kura Oncology, Inc. (KURA) Solid Tumors With HRAS Alterations | Phase 1 |
Clinical Trial Registry Records (1)
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors
Primary endpoint: Rate of dose-limiting toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with darlifarnib?
darlifarnib has dated SEC/FDA relationship records for Kura Oncology, Inc..
How many clinical trials involve darlifarnib?
BioSniper tracks 1 clinical trial involving darlifarnib.